Creating a Master Application for a Migrated Study

(1) This workflow will need to occur before submitting a continuing review or amendment for a migrated study.

1. From the homepage in iRIS, click Find a Study.



2. Enter the legacy IRB Number (i.e. 21D.1016)

	Caler
IRB Number:	
Study Status: All	
Study Classification: All	
Reference Number:	
Include Studies that have not been assigned an IRB Number:	

3. Click Find.



4. Click Open.

1 result(s) found...

Open	Study Status	IRB Number	IR
Ø	Approved With No Further Continuing Review	21D.1016	01/0

5. Click on Study Application.

L		
Submissions	Study Management	
Protocol Items		
Study Ap	plication	
	Consents 🕑	
Other Stu	dy Documents 🛛 Þ	
Submission For	ns	
6. Click on Add a n	ew Application.	
		N Daux
ry Care Motivation	al Interviewing Nutrition	Education Program for Weight Loss
		Add a new Application
Approved?		Approval Date

7. For section 1.0 and 2.0, bypass them by clicking Save and Continue to Next Section (Note: If the personnel listed are not correct, you will need to submit a personnel change form).



8. Answer the questions in Section 4.0. Department: TJU - Office of Human Research (OHR) Path: Home > find study > study right: > application list	🗮 Calendar 🕜 Help	🚊 My Profile 🗢 🕒 Log out
Number: 21D.1016 Cheng, Cynthia Study Entire view of the Application Version 1.0)	Print Friendly Save Section	Back Save and Continue to Next Section
4.0 Determination Section		
4.1 Is your study's objective, aim, eligibility, or outcome pre-cancer or cancer-related? ○ Yes ○ No		
4.2 Does you study include Written, Verbal and/or Implied consent process?		
⊖ Yes ⊖ No		3
4.4 Was approved or authorized by Jefferson IRB and issued a Jefferson IRB number prior to the IRIS Go Live study in IRIS), enter the Jefferson IRB number here. This will ensure that the Jefferson IRB number is ass	date of 09/26/2022, and was not migrate igned to this study in iRIS.	d to iRIS (i.e., you cannot find the
○ Yes ○ No		

Calendar	? Help	💄 My Profile 👻	€ Log out
			🚺 Back
Print Friendly	Save Section	Save and Continue t	o Next Section
10. Answer the questions	in Section 5.0.		
Department: TJU - Office of Human Research (OHR) Path: Home > find study > study mgmt. > application	list	Calendar (?) H	elp 🙎 My Profile ⊽ 🕞 Log out
Yumber: 21D.1016 Cheng, Cynthia Study Master Applic	ation (Version 1.0)		🚺 Back
Entire view of the Application		Print Friendly Save Se	Save and Continue to Next Section
5.0	Selecting	IRB of Record	
5.1 Is this a multi-site study that is or is intended	to be under single IRB oversight (i.e.,	study involves non-Jefferson/Rothman sites. Contact OH	R with questions.)
O Yes 💿 No			
5.3 Select IEB of Record:			
 Jefferson NCI CIRB Commercial IRB (e.g. WIRB, Advarra, etc.) Academic or other external IRB 			Ŵ

	Calendar	? Help	My Profil	e - 🚺	E Log out
				K	Back
	Print Friendly	Save Section			t Section
ion	/Rothman sites. Co	ntact OHR with (questions.)		
12.	Answer the questions Account: Steven Muller Department: TUJ - Office of Human Research (O Path: Home > find study > study memt. > applie	In Section 6.0.	i	Calendar 🛞 Help	🚊 My Profile 🐖 💽 Log
IRB N PI:	Entire view of the Application	plication (Version 1.0)	Print Fri	iendly Save Section	Ba Ba Save and Continue to Next Sec
	6.0	General In	formation (OHR-1)		
d	6.1 Funding Sponsor name:	Sponsor Type	Project Number	Award Number	
	No Sponsor has been added to this Study				
	6.2 Division:				
	Non-Oncology:	5,4 J			
	6.3 Does this study involve only data collection	n with no interactions with participants	,		
	O Yes O No				
	6.4 Does this study involve only collection of	tored or discarded biospecimens, with o	or without data collection, and with no in	teractions with participan	its?"

Calendar ? Help	Profile → C>Log out
	🖪 Back
Print Friendly Save Section	Save and Continue to Next Section
ss operations. Please contact:	
14. Answer the questions in Section 7.0. Account: Steven Muller Department: TUU - Office of Human Research (OHR) Path: Home > find study > study mgmt. > application list INB Number: 21D.1016 Study Pat: Cheng. Cynthia	🔠 _{Calendar} 🕧 Help 🔹 My Profile 🗸 Co Log
n Entire view of the Application	Print Friendly Save Section Save and Continue to Next Sec
7.0 Study Overs 7.1 Brief Summary:	view (OHR-2)
Provide a brief (2-3 sertences) lay language synopsis of the study: a	1 ∨ ¶ ∨ E × 归 ∨ 田 × 田 №

Calenda	ar 🕐 Help	💄 My Profile 🗸	€ Log out
			🚺 Back
Print Friendly	Save Section		
16. Answer the questi	ons in Section 8.0. (if a	oplicable)	
Account: Steven Muller Department: TJU - Office of Human Ru Path: Home > find study > study mon	esearch (OHR) st. > arealstation list	Calendar	🛞 Help 🙎 My Profile 🗵 💽 Lo
IRB Number: 21D.1016 Study Ma	aster Application (Version 1.0)		🚺 Bā
entire view of the Application		Print Friendly	Save Section Save and Continue to Next Sec
8.0	Subjects and	Facilities (OHR-2)	
8.1 Does study involve <u>only</u> the colic	ection of tissue and/or data where there will be no	interaction with human subjects?	
O Yes O No			
8.2 What is the expected number of	subjects to be enrolled?		
Number of subjects per year at sites	s under Jefferson IRB (up to):		
Total number of subjects for duration	on of study under Jefferson JRB (up to):		
Total number of subjects nationally	or internationally for duration of study (if applicab	le):	
6.3 Identify the locations where the	research will be conducted and describe the adequ	uacy of facilities at each location:	

	🔲 Calendar	? Help	💄 My Profile 🤸	G	Log out
					Back
	Print Friendly	Save Section	Save and Continu	e to Next	Section
je	cts?				
18.	Answer the questions	in Section 9.0. (if a	pplicable)		
	Account: Steven Muller Department: TJU - Office of Human Research (Path: Home > find truck > cturk mount > and	DHR)	Calenda	r 🕐 Help	🚊 My Profile 👳 🕞 Log
IRB	Number: 21D.1016 Study Master A	pplication (Version 1.0)			🖪 Ba
	Entire view of the Application		Print Friendly	Save Section	Save and Continue to Next Sec
	9.0	Dri	ıgs (OHR-2)		
	9.1 Does this study involve investigational o	r emergent use of drug(s) (ie., investiga	tional drugs, FDA approved drugs, nutritional sup	plements, biological	5)?
d	○ Yes ○ No Note: "Investigational use" should be applied to study design.	a drug that is under study in the research, is	a comparator in a randomized study design, or is othe	rwise integral to the	
	9.4 If the investigational product does not h checking applicable statement(s). If not	ave an IND#, please certify that its inter ie of the following categories apply, the	ded use meets <u>at least one</u> of the following FDA sponsor must obtain an IND# or IND exemption	categories for IND ex letter from the FDA.	comption (21 CFR 312.2) by
	Exemption Category 1 [21 CFR 312.2(b)(1)]	- All criteria for this category must apply:			
	The drug product is lawfully marketed in the it is not intended to be reported to FDA in su it is not intended to support a significant cha t does not involve a route of administration acceptability of the risks) associated with the use it is conducted in compliance with the requir t is conducted in compliance with the requir	United States. pport of a new indication for use or to suppor nge in the advertising for the product; or dosage level, use in a subject population, of the drug product; ments for IRB review and informed consent ments concerning the promotion and sale of	t any other significant change in the labeling for the d or other factor that significantly increases the risks (or [21 CFR parts 56 and 50, respectively]; and drugs [21 CFR 312.7].	rug; decreases the	
	In Vitro Diagnostic Biological Product [21 CFF	312.2(b)(2)]:			
	The study is a clinical investigation involving be used in a diagnostic procedure that confirms t Sec. 312.160.	a (a) blood grouping serum; (b) reagent red he diagnosis made by another, medically esta	blood cells; and/or (c) anti-human globulin and the pr blished, diagnostic product or procedure and it is shipp	oduct is intended to ed in compliance with	

	Calen	dar ? Help	🚊 My Profile 👻	C Log out	
				🚺 Back	
	Print Friendly	Save Section			
ug	s, nutritional s	upplements, biologi	cals)?		
20.	Answer the ques Account: Steven Muller Department: 'JU - Office of Human Path: 'Kome > find study > study wa	stions in Section 10.0. (Research (OHR) grot. > application list	if applicable) if _{catendar}	👔 Help 🙎 My Profile 🗸 🕒	Log
IRB N PI: (Entire view of the Application	Master Application (Version 1.0)	Print Friendly	Save Section Save and Continue to Next S	Bac Secti
- 1	10.0	Ĩ	Devices (OHR-2)		
	10.1 Does this study involve inves	stigational or emergent use of a device or humani	tarian use device (HUD)?		
,	10.11 When the investigator or Je regulatory criteria for spons	fferson holds the IDE/HDE, the Investigator/Jeff sors are met. Please provide your plan for meeting	erson becomes the "sponsor" of the research and assu g FDA regulatory criteria for sponsors:	mes responsibility to ensure that all FDA	
	For example: Investigator who holds an IDE, Investigator will undergo an au Investigator will assign respon procedures are in place so that	/HDE will assign some or all responsibilities to meet FD udit by a CR0 to ensure that procedures are in place so sibility of compliance with some FDA regulatory require 1 all other FDA regulatory requirements of somosors will	A sponsor requirements to a contract research organization (that all FDA regulatory requirements of sponsors will be met ments to a CRO and investigator will obtain an audit from a (be met.	CRO). RO to ensure that	

	🔳 Calendar	? Help	Q My Profile	•	⇒Log out
					Back
	Print Friendly	Save Section	Save and Conti	nue to Nexi	Section
				_	
22.	Answer the questions Account: Steven Muller Department: TJU - Office of Human Research (0 Path: Home > find study > study mgmt. > appl Humber: 21D.1016 Study Master A	in Section 11.0. (if when the section late to the section late to the section late to the section (version 1.0)	applicable) iiii _{cal}	endar 💮 Help	🚊 My Profile 🗸 💽 Da
PT:	Entire view of the Application		Print Friend	lly Save Section	Save and Continue to Next Sec
	11.0	Risk, Benefits	& Alternatives (OHR-2)		
n rd	11.1 What are the risks of the research? Please note: This is not the same as the descript Examples include: time commitment requirement questionnaires, etc	ion of the known side effects of the test arti that impinge on daily activities, study drug	cle(s). ineffective, unpredicted adverse effects or drug in	iteractions, anxiety about	
	11.2 Discuss how the study design minimize	s risks and maximizes benefits associate	ed with this study:		
	Consider number of subjects required to answer t	he research question, frequency of tests for	adverse events, specific exclusion criteria, etc.		
	11.3 What are the potential benefits of partie	ipation?			

Calendar	? Help	🚊 My Pr	ofile 🗸	C> Log o	out
				🔣 Bacl	k
Print Friendly	Save Section				
					Î
24. Answer the questions	in Section 12.0. (if	applicable)			
Account: Steven Muller Department: TJU - Office of Human Research (OHR) Path: Home > find study > study mgnt. > application li	st	Ē	Calendar 🧿 Help	🙎 My Profile 🗢	€ Log out
Number: 21D.1016 Cheng, Cynthia Study Master Applica	tion (Version 1.0)				🖪 Back
Entire view of the Application		Print F	riendly Save Section	Save and Continue to	Next Section
12.0	Recruitment & Cons	ent Process (OHR-2)			
12.1 Do you intend to obtain consent from the partic	cipants for this study?				
○Yes ○No					

Calendar	? Help	🚊 My Pre	ofile 🗸	🕒 Log o	out		
				🔣 Bac	k		
Print Friendly	Save Section						
-2)							
26. Answer the questions in Section 13.0. (if applicable)							
Account: Steven Muller Department: TJU - Office of Human Research (OHR) Path: Home > find study > study mgmit. > application &	st	iii) (Calendar 🕧 Help	🧕 My Profile 👻	C⇒ Log out		
Number: 21D.1016 Cheng, Cynthia Study Master Applica	tion (Version 1.0)				🖪 Back		
Entire view of the Application		Print Fri	iendly Save Section	Save and Continue to	o Next Section		
13.0	Rad	iation					
13.1 Does this study involve the use of radioactive r	naterial or radiation source?						
⊖Yes ⊖No							

	Calendar	? Help	•	My Profile 🚽		≻Log out	
					K	Back	
	Print Friendly	Save Section					
28	8. Answer the questions Account: Steven Muller Department: TJU - Office of Human Research (Ol Path: Home > find study > study mgmt, > applis	in Section 15.0. (if	f applica	ble) Equation Colored on the C	🕐 Help	🚊 My Profile 🗸 💽 Lo	
IR PI	BR Number: 21D.1016 Study Master Ap tr Cheng, Cynthia Study Master Ap	plication (Version 1.0)		Print Friendly	Save Section	Ba Ba	
	15.0	Data Collection &	Waiver of Con	sent (OHR-3/4)			
n rd	Under the Common Rule, the IRB may waive the re Under HIPAA, the IRB also may waive the requiren criteria apply.	equirement for written consent, or the cons ent to obtain written authorization for use	sent process as a wi of protected health	hole, when certain criteria apply. information (PHI) for research purpo	ses, when certain	(?)	
	15.2 Please list all data that will be collected to	for this study:					
,	This includes all study data, including health-relate	d dətə and identifiers.					
tt 15.3 What are the specific sources of the data to be collected? (i.e., Dr. X's outpatient records, hospital EMR, Pathology records, etc.)							
on ver							
	15.4 Complete the table below by checking as	applicable:					

Calendar	? Help	💄 My Profile 🗸	🕒 Log out					
			🚺 Back					
Print Friendly	Save Section							
-3/4)								
		6						
30. Answer the questions in Section 16.0.								
Account: Steven Muller Department: TJU - Office of Human Research (OHR) Path: Home > find study > study rogmt. > application lis	st	🖀 Calendar 🤃 Help	🚊 My Profile 👻 🕒 Log out					
Study Master Application Cheng, Cynthia	tion (Version 1.0)		🚺 Back					
Entire view of the Application		Print Friendly Save Section	Save and Continue to Next Section					
16.0 Application Complete								
16.1 Click Save & Continue to proceed to the Initial Review Submission Packet.								
The Initial Review Submission Packet is a short form filled out after the protocol application has been completed. This is an area to attach protocol-related documents, consent forms, and review the application.								

31. You will be routed to attach protocol-related documents, consent forms, and review the application.

This Workflow was created with Tango.